Advertisement
Screener

JASPER THERAPEUTICS, INC. (JSPR) Graph

JSPR Revenue Flow

A current filed revenue breakdown could not be established from the retained filing evidence.

  • 2019-08-30: Net income -$1.00K.

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 1 month

Period endNet income
2019-08-30-$1.00K

Revenue and expense 3 month

Period endCost of revenueResearch and developmentOperating expensesIncome taxNet income
2026-06-30$3.58M$5.13M$9.21M(m)-$2.76M
2026-03-31$3.62M$5.81M$10.95M(m)-$1.17M
2025-12-31$6.76M*$11.36M*$15.84M*(m)(m)
2025-09-30$9.35M$14.39M$19.17M(m)-$18.74M
2025-06-30$15.77M$21.20M$27.08M(m)-$26.72M
2025-03-31$9.76M$16.16M$21.80M(m)-$21.24M
2024-09-30$8.78M$14.46M$19.89M(m)-$18.64M
2024-06-30(m)$11.30M$15.99M(m)-$14.58M
2024-03-31(m)$10.30M$15.07M(m)-$13.73M
2023-09-30(m)$14.85M$19.36M(m)-$17.54M
2023-06-30(m)$13.30M$17.83M(m)-$16.08M
2023-03-31(m)$9.80M$13.95M(m)-$14.26M
2022-09-30(m)$9.02M$12.71M(m)-$11.86M
2022-06-30(m)$8.13M$11.96M(m)-$10.40M
2022-03-31(m)$8.19M$12.78M(m)-$2.21M
2021-09-30(m)$7.19M$10.08M(m)-$3.41M
2021-06-30(m)$5.16M$8.42M(m)-$8.41M
2021-03-31(m)$4.42M$6.25M(m)-$9.75M
2020-09-30(m)$4.52M$6.01M-$8.21K-$201.19K
2020-06-30(m)(m)(m)-$1.20K-$3.43M
2020-03-31(m)(m)(m)$57.82K$1.43M

Revenue and expense 5 month

Period endIncome taxNet income
2019-12-31$16.23K-$596.38K

Revenue and expense 6 month

Period endCost of revenueResearch and developmentOperating expensesIncome taxNet income
2026-06-30$7.21M$10.95M$20.16M(m)-$3.93M
2025-06-30$25.53M$37.35M$48.88M(m)-$47.96M
2024-06-30(m)$21.59M$31.07M(m)-$28.31M
2023-06-30(m)$23.10M$31.77M(m)-$30.34M
2022-06-30(m)$16.32M$24.74M(m)-$12.61M
2021-06-30(m)$9.58M$14.67M(m)-$18.17M
2020-06-30(m)(m)(m)$56.63K-$2.00M

Revenue and expense 9 month

Period endCost of revenueResearch and developmentOperating expensesIncome taxNet income
2025-09-30$34.87M$51.74M$68.04M(m)-$66.70M
2024-09-30$21.10M$36.05M$50.95M(m)-$46.95M
2023-09-30(m)$37.95M$51.14M(m)-$47.88M
2022-09-30(m)$25.34M$37.45M(m)-$24.47M
2021-09-30(m)$16.76M$24.75M(m)-$21.58M
2020-09-30(m)$11.24M$14.72M$48.41K$21.68M

Revenue and expense 12 month

Period endCost of revenueResearch and developmentOperating expensesIncome taxNet income
2025-12-31$41.63M$63.10M$83.88M(m)-$75.80
2024-12-31$34.27M$55.82M$76.24M$2.00K-$71.30M
2023-12-31(m)$51.78M$68.86M$2.00K-$64.50M
2022-12-31(m)$34.63M$51.20M(m)-$37.69M
2021-12-31(m)$25.42M$36.83M(m)-$30.64M
2020-12-31(m)$15.88M$20.68M$38.45K-$31.67M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Estrella Immunopharma, Inc. (ESLA)United States$0.020B
BioCardia, Inc. (BCDA)United States$0.016B
DYADIC INTERNATIONAL INC (DYAI)United States$0.016B
Passage BIO, Inc. (PASG)United States$0.015B-0.43
Pluri Inc. (PLUR)$0.014B
INTENSITY THERAPEUTICS, INC. (INTS)United States$0.013B-1.08
BRAINSTORM CELL THERAPEUTICS INC. (BCLI)United States$0.013B-1.05
IN8BIO, INC. (INAB)United States$0.012B-0.76
Senti Biosciences Holdings, Inc. (SNTI)United States$0.011B-0.70
CEL SCI CORP (CVM)United States$0.030B-0.81